

# Achieve Life Sciences Inc

06:53 03 Apr 2019

## Achieve Life Sciences shares rise as data safety committee finds no issues with smoking cessation trial

Achieve Life Sciences Inc (NASDAQ:ACHV) shares swirled a bit higher Tuesday as the biotech revealed that the data safety monitoring committee (DSMC) had no issues with its trial of smoking-cessation drug cytisinicline.

The Phase 2b trial called ORCA-1 should continue, it said, while topline efficacy and safety data are expected by the end of the second quarter of 2019.

**READ:** Achieve Life Sciences shares rocket after a promising smoking-cessation drug trial

Cytisinicline is a plant-based alkaloid and has been an approved, branded product in Central and Eastern Europe for more than two decades to help combat nicotine addiction.

The data safety committee has reviewed the ORCA-1 data twice during the study, and has concluded following each review that there are no safety concerns for subjects or study conduct issues.

The trial is evaluating a 25-day treatment course of 1.5 mg or 3 mg doses of cytisinicline using either a declining titration schedule or three times daily. The trial is randomized and blinded to compare the effectiveness of the cytisinicline doses and schedules to respective placebo groups.

The primary efficacy endpoint is the overall reduction in the number of cigarettes smoked during the treatment period.

Shares in Achieve Life Sciences added 1.8% in New York to stand at \$3.23

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and

**Price:** 0.316

**Market Cap:** \$9.91 m

### 1 Year Share Price Graph



### Share Information

**Code:** ACHV

**Listing:** NASDAQ

52 week	High	Low
	4.61	0.23

**Sector:**

**Website:** [achievelifesciences.com](http://achievelifesciences.com)

### Company Synopsis:

*Achieve Life Sciences is a clinical-stage pharmaceutical group that specializes in smoking cessation techniques.*

[action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.